Fate Therapeutics (FATE) Tops Q3 EPS by 3c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.36 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
• Chargepoint Holdings Inc. (CHPT) Tops Q2 EPS by 25c, Beats on Revenue
• Five Below raises full-year outlook after strong second-quarter sales growth